[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fRrM4GZ0-1UONjj2odCSMTsbXIaUmJ6x-h2VBn69imks":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":41,"rows":48},"Pakistan Institute of Living and Learning",[4],58,false,12,2,42689,1,48,[14,17,20,23,25,28,30,33],{"name":15,"count":16},"Depression",10,{"name":18,"count":19},"Psychosis",7,{"name":21,"count":22},"Schizophrenia",6,{"name":24,"count":22},"Schizoaffective Disorder",{"name":26,"count":27},"Self Harm",5,{"name":29,"count":27},"Maternal Depression",{"name":31,"count":32},"Suicidal Ideation",4,{"name":34,"count":32},"Schizophreniform Disorder",[36],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT07015944","Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in Pakistan","2028-12-30","Standardised pharmacological treatment",[42,43,44,45,46,47],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[49,73,136,162,180,217,239,266,284,302,320,338,356],{"intervention":40,"totalTrials":11,"cells":50},{"EARLY_PHASE1":51,"PHASE1":54,"PHASE2":56,"PHASE3":58,"PHASE4":60,"NA":62},{"trials":52,"activeCount":53},[],0,{"trials":55,"activeCount":53},[],{"trials":57,"activeCount":53},[],{"trials":59,"activeCount":53},[],{"trials":61,"activeCount":53},[],{"trials":63,"activeCount":11,"soonestReadout":39},[64],{"nctId":37,"briefTitle":38,"status":65,"phases":66,"primaryCompletion":39,"completion":39,"start":67,"enrollment":68,"conditions":69,"interventions":72},"RECRUITING",[47],"2025-06-13",26376,[70,71],"Major Depressive Disorder (MDD)","Breast Cancer Survivor",[40],{"intervention":74,"totalTrials":32,"cells":75},"Minocycline",{"EARLY_PHASE1":76,"PHASE1":78,"PHASE2":90,"PHASE3":106,"PHASE4":120,"NA":134},{"trials":77,"activeCount":53},[],{"trials":79,"activeCount":53},[80],{"nctId":81,"briefTitle":82,"status":83,"phases":84,"primaryCompletion":85,"completion":85,"start":86,"enrollment":87,"conditions":88,"interventions":89},"NCT02533232","Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia","UNKNOWN",[43],"2022-12-30","2022-08-30",60,[21,24,34],[74],{"trials":91,"activeCount":53},[92],{"nctId":93,"briefTitle":94,"status":95,"phases":96,"primaryCompletion":97,"completion":98,"start":99,"enrollment":100,"conditions":101,"interventions":103},"NCT02569307","Minocycline and\u002For Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States","COMPLETED",[44],"2018-12","2019-03","2015-10",326,[102,18],"At Risk Mental State (ARMS)",[74,104,105],"Omega-3 fatty acids","Minocycline Plus Omega-3 fatty acids",{"trials":107,"activeCount":53},[108],{"nctId":109,"briefTitle":110,"status":95,"phases":111,"primaryCompletion":97,"completion":97,"start":112,"enrollment":113,"conditions":114,"interventions":118},"NCT02703363","Minocycline and Celecoxib as Adjunctive Treatments of Bipolar Depression",[45],"2016-08",265,[15,115,116,117],"Bipolar Disorder","Bipolar Depression","Mood Disorders",[74,119],"Celecoxib",{"trials":121,"activeCount":53},[122],{"nctId":123,"briefTitle":124,"status":95,"phases":125,"primaryCompletion":126,"completion":112,"start":127,"enrollment":128,"conditions":129,"interventions":133},"NCT02263872","Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial",[46],"2016-06","2014-10",41,[130,117,131,132],"Depressive Disorder","Depressive Disorder, Treatment Resistant","Antidepressive Agents",[74],{"trials":135,"activeCount":53},[],{"intervention":137,"totalTrials":11,"cells":138},"Simvastatin 20 mg",{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":143,"PHASE3":145,"PHASE4":158,"NA":160},{"trials":140,"activeCount":53},[],{"trials":142,"activeCount":53},[],{"trials":144,"activeCount":53},[],{"trials":146,"activeCount":53},[147],{"nctId":148,"briefTitle":149,"status":95,"phases":150,"primaryCompletion":151,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":157},"NCT03435744","Simvastatin as an Augmentation Treatment for Treatment Resistant Depression: Randomized Controlled Trial.",[45],"2021-06-30","2019-01-01",150,[155,156],"Treatment Resistant Depression","Major Depressive Disorder",[137],{"trials":159,"activeCount":53},[],{"trials":161,"activeCount":53},[],{"intervention":119,"totalTrials":11,"cells":163},{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":176,"NA":178},{"trials":165,"activeCount":53},[],{"trials":167,"activeCount":53},[],{"trials":169,"activeCount":53},[],{"trials":171,"activeCount":53},[172],{"nctId":109,"briefTitle":110,"status":95,"phases":173,"primaryCompletion":97,"completion":97,"start":112,"enrollment":113,"conditions":174,"interventions":175},[45],[15,115,116,117],[74,119],{"trials":177,"activeCount":53},[],{"trials":179,"activeCount":53},[],{"intervention":181,"totalTrials":9,"cells":182},"Ondansetron",{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":199,"PHASE3":211,"PHASE4":213,"NA":215},{"trials":184,"activeCount":53},[],{"trials":186,"activeCount":53},[187],{"nctId":188,"briefTitle":189,"status":95,"phases":190,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":195,"interventions":197},"NCT00929955","Role of Anti-Inflammatory Agents in Patients With Schizophrenia",[43],"2009-09","2010-09","2009-06",36,[21,24,196,34],"Psychosis Not Otherwise Specified",[181,198],"Simvastatin",{"trials":200,"activeCount":53},[201],{"nctId":202,"briefTitle":203,"status":95,"phases":204,"primaryCompletion":205,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":209},"NCT01602029","Randomized Double Blind Placebo Control Study in Patients with Schizophrenia",[44],"2013-06","2010-08",303,[21,24,196,34],[181,198,210],"Odansetron plus simvastatin",{"trials":212,"activeCount":53},[],{"trials":214,"activeCount":53},[],{"trials":216,"activeCount":53},[],{"intervention":198,"totalTrials":9,"cells":218},{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":227,"PHASE3":233,"PHASE4":235,"NA":237},{"trials":220,"activeCount":53},[],{"trials":222,"activeCount":53},[223],{"nctId":188,"briefTitle":189,"status":95,"phases":224,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":225,"interventions":226},[43],[21,24,196,34],[181,198],{"trials":228,"activeCount":53},[229],{"nctId":202,"briefTitle":203,"status":95,"phases":230,"primaryCompletion":205,"completion":205,"start":206,"enrollment":207,"conditions":231,"interventions":232},[44],[21,24,196,34],[181,198,210],{"trials":234,"activeCount":53},[],{"trials":236,"activeCount":53},[],{"trials":238,"activeCount":53},[],{"intervention":240,"totalTrials":11,"cells":241},"Sodium Benzoate",{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":260,"PHASE4":262,"NA":264},{"trials":243,"activeCount":53},[],{"trials":245,"activeCount":53},[],{"trials":247,"activeCount":53},[248],{"nctId":249,"briefTitle":250,"status":95,"phases":251,"primaryCompletion":252,"completion":253,"start":152,"enrollment":254,"conditions":255,"interventions":257},"NCT03510741","Sodium Benzoate and\u002For N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.",[44],"2020-12-30","2021-03-30",64,[21,256,24],"Schizophreniform Disorders",[240,258,259],"N-Acetylcysteine","Sodium Benzoate Plus N-Acetylcysteine",{"trials":261,"activeCount":53},[],{"trials":263,"activeCount":53},[],{"trials":265,"activeCount":53},[],{"intervention":258,"totalTrials":11,"cells":267},{"EARLY_PHASE1":268,"PHASE1":270,"PHASE2":272,"PHASE3":278,"PHASE4":280,"NA":282},{"trials":269,"activeCount":53},[],{"trials":271,"activeCount":53},[],{"trials":273,"activeCount":53},[274],{"nctId":249,"briefTitle":250,"status":95,"phases":275,"primaryCompletion":252,"completion":253,"start":152,"enrollment":254,"conditions":276,"interventions":277},[44],[21,256,24],[240,258,259],{"trials":279,"activeCount":53},[],{"trials":281,"activeCount":53},[],{"trials":283,"activeCount":53},[],{"intervention":259,"totalTrials":11,"cells":285},{"EARLY_PHASE1":286,"PHASE1":288,"PHASE2":290,"PHASE3":296,"PHASE4":298,"NA":300},{"trials":287,"activeCount":53},[],{"trials":289,"activeCount":53},[],{"trials":291,"activeCount":53},[292],{"nctId":249,"briefTitle":250,"status":95,"phases":293,"primaryCompletion":252,"completion":253,"start":152,"enrollment":254,"conditions":294,"interventions":295},[44],[21,256,24],[240,258,259],{"trials":297,"activeCount":53},[],{"trials":299,"activeCount":53},[],{"trials":301,"activeCount":53},[],{"intervention":210,"totalTrials":11,"cells":303},{"EARLY_PHASE1":304,"PHASE1":306,"PHASE2":308,"PHASE3":314,"PHASE4":316,"NA":318},{"trials":305,"activeCount":53},[],{"trials":307,"activeCount":53},[],{"trials":309,"activeCount":53},[310],{"nctId":202,"briefTitle":203,"status":95,"phases":311,"primaryCompletion":205,"completion":205,"start":206,"enrollment":207,"conditions":312,"interventions":313},[44],[21,24,196,34],[181,198,210],{"trials":315,"activeCount":53},[],{"trials":317,"activeCount":53},[],{"trials":319,"activeCount":53},[],{"intervention":104,"totalTrials":11,"cells":321},{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":332,"PHASE4":334,"NA":336},{"trials":323,"activeCount":53},[],{"trials":325,"activeCount":53},[],{"trials":327,"activeCount":53},[328],{"nctId":93,"briefTitle":94,"status":95,"phases":329,"primaryCompletion":97,"completion":98,"start":99,"enrollment":100,"conditions":330,"interventions":331},[44],[102,18],[74,104,105],{"trials":333,"activeCount":53},[],{"trials":335,"activeCount":53},[],{"trials":337,"activeCount":53},[],{"intervention":105,"totalTrials":11,"cells":339},{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":350,"PHASE4":352,"NA":354},{"trials":341,"activeCount":53},[],{"trials":343,"activeCount":53},[],{"trials":345,"activeCount":53},[346],{"nctId":93,"briefTitle":94,"status":95,"phases":347,"primaryCompletion":97,"completion":98,"start":99,"enrollment":100,"conditions":348,"interventions":349},[44],[102,18],[74,104,105],{"trials":351,"activeCount":53},[],{"trials":353,"activeCount":53},[],{"trials":355,"activeCount":53},[],{"intervention":357,"totalTrials":11,"cells":358},"Methotrexate",{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":373,"PHASE3":375,"PHASE4":377,"NA":379},{"trials":360,"activeCount":53},[],{"trials":362,"activeCount":53},[363],{"nctId":364,"briefTitle":365,"status":95,"phases":366,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":371,"interventions":372},"NCT02074319","RCT of Methotrexate Added to Treatment As Usual in Schizophrenia",[43],"2015-07","2015-08","2013-12",92,[21,24,34],[357],{"trials":374,"activeCount":53},[],{"trials":376,"activeCount":53},[],{"trials":378,"activeCount":53},[],{"trials":380,"activeCount":53},[]]